An Open-Label, Single-Arm, Multicenter, Study of Telbivudine in Nucleos(t)Ide-naive Subjects of Black/African American or Hispanic/Latino Origin With Compensated Chronic Hepatitis B Virus (HBV) Infection.
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Telbivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 22 Sep 2016 Status changed from discontinued to withdrawn prior to enrolment.
- 01 Nov 2011 Planned end date changed from 1 Aug 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 01 Nov 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.